Novel Markers of Arterial Dysfunction
|
|
- Beverly Rodgers
- 5 years ago
- Views:
Transcription
1
2 혈관연구회창립심포지움, 3 월 3 일, 2005 Novel Markers of Arterial Dysfunction Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon Medical School Incheon, Korea
3 Atherosclerosis: A progressive process PHASE I: Initiation PHASE II: Progression PHASE III: Complication Disease progression
4 Nitric Oxide Regulates vasomotor tone Inhibits inflammatory cell attachment Inhibits platelet aggregation and attachment Inhibits release of procoagulant factors Inhibits release of growth factors Koh KK. Cardiovasc Res 2000;47:648 (Review) Koh KK. Cardiovasc Res 2002;55:714 (Review)
5 Baseline 1
6
7 Reactive Hyperemia
8
9 Baseline 1 Reactive Hyperemia
10 40 Subjects with a Parental History of Premature Myocardial Infarction N Engl J Med 2000; 343: 840
11 Sensitivity and Specificity of Tests in Predicting CAD Test Sensitivity (95% CI) Specificity (95% CI) Angina Pectoris (n = 112) Exercise ECG testing (n = 112) Myocardial Perfusion Imaging (n = 34) 96/101; 95.1% ( ) 5/21; 23.8% ( ) 75/91; 82.4% ( ) 12/21; 57.1% ( ) 30/30; 100.0% ( ) 0/4; 0.0% (0-60.2) FMD% (n = 122) 72/101; 71.3% ( ) 17/21; 81% ( ) Schroeder et al. Am Heart J 1999;138:731
12 Kaplan-Meier Analysis of Patients w/o CV Events (10 yrs) Schachinger et al. Circulation 2000;101:1899
13 Inflammatory Response to Injury TxA 2 vwf Tissue Factor Adhesion Molecules Chemokines Cytokines Cytokines Growth Factors Metalloproteinases Colony Stimulating Factors Growth Factors Reactive Oxygen Species LDL Oxidation
14 Cytokines LDL ox Ang II LPS CMV NADH / NADPH oxidase Cyclooxygenase Lipoxygenase Xanthine oxidase Mitochondria Activation of Nuclear Transcription Factor, NFkB NO, HDL Antioxidant LDL, Lp(a) Oxygen Free Radicals p50 p65 MCP-1 M-CSF E Selectin ICAM-1 VCAM-1 Tissue factor PAI-1 p65 p50 IkB IkB P Koh KK. Cardiovasc Res 2002;55:714 (Review)
15 PDGF complement thromboxane A 2 metalloproteinases tissue factor PAI-1 oxygen free radicals Adhesion Molecule Expression IL-1 TNF Lymphocyte Activation IL-6 IL-11 Cytokines Initiate Hepatic Synthesis of Some Proteins (Acute Phase Reactants C-reactive protein amyloid A haptoglobin ceruloplasmin C3, C4 fibrinogen vwf PAI-1 Lp(a) + - albumin transferrin A-I, A-II + C3 amyloid A a 1 -acid glycoprotein Koh KK. Cardiovasc Res. 2002;55:714. (Review)
16 Association Between MCP-1 Levels and Prevalence of Subclinical Atherosclerosis In Dallas Heart Study, 3,499 subjects <65 yrs Coronary artery calcium measured by EBCT Deo R, et al. JACC 2004;44:1812
17 CRP, Metabolic Syndrome, and Prediction of CV Events in the Framingham Offspring Study Both CRP and MetS are independent predictors of new CVD events over 7 years Rutter MK, et al. Circulation. 2004;110:380.
18 Top, Rapid angiographic stenosis progression Classified according to sicam-1 and CRP levels. Bottom, according to neopterin and MMP-9 levels P<0.001 P<0.001 Zouridakis E. Circulation. 2004; 110:1747.
19 Adiponectin, cytokines secreted by adipose cells, Have insulin-sensitizing, anti-inflammatory, And anti-atherogenic properties Adiponectin Adiponectin Receptor AMPK enos reductase PI 3-kinase-dependent Pathways p reductase oxydase L-Arginine oxydase L-Citruline NO NFkB p65 p50 IkB IkB P p50 p65 Han SH, et al. Circulation (Review, submitted)
20 Therapeutic Intervention Cytokines LDL ox Ang II LPS CMV NADH / NADPH oxidase Cyclooxygenase Lipoxygenase Xanthine oxidase Mitochondria Ramipril, ARBs Fenofibrate Oxygen Free Radicals p50 p65 MCP-1 M-CSF E Selectin ICAM-1 VCAM-1 Tissue PAI-1 factor p65 p50 IkB IkB P Fenofibrate HDL, NO Antioxidant TG, LDL
21 Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels In Patients With Primary Hypertriglyceridemia Kwang Kon Koh, Seung Hwan Han Eak Kyun Shin,. Michael J. Quon* Diabetes Unit, NIH, USA* ACC 2005, Orlando, USA Diabetes Care 2005 (in press)
22 Effects of Fenofibrate on Inflammation in 46 Hypertriglyceridemic Patients Fibrinogen (mg/dl) 1.0 hscrp (mg/l) P< % P= ( ) 0.70 ( ) Placebo Fenofibrate 0.0 Placebo Fenofibrate
23 Additive Beneficial Effects of Fenofibrate Combined with Atorvastatin In Treatment of Combined Hyperlipidemia Kwang Kon Koh, Seung Hwan Han Eak Kyun Shin,. Michael J. Quon* Diabetes Unit, NIH, USA* ACC 2005, Orlando, USA JACC 2005 (in press)
24 Combined therapy or fenofibrate alone significantly increases Adiponectin levels in patients with combined hyperlipidemia 30 % Change in Adiponectin Levels (%) P<0.05 P<0.05 P=0.022 by ANOVA 0 Atorvastatin Combined Therapy Fenofibrate
25 Combined therapy or fenofibrate alone significantly increases Insulin sensitivity in patients with combined hyperlipidemia 15 % Change in QUICKI (%) 10 5 P<0.05 P=0.049 by ANOVA 0 Atorvastatin Combined Therapy Fenofibrate *QUICKI=Quantitative Insulin-Sensitivity Check Index, a surrogate index of insulin sensitivity, QUICKI = 1/[log(insulin)+log(glucose)]
26 Ramipril Combined with Simvastatin on MCP-1 Levels (pg/ml) (HC) P= P=0.019 P< Baseline 1 Simvastatin +Placebo 0 Baseline 2 Simvastatin +Ramipril Koh KK, et al. Hypertension. 2004;44:180
27 200 Simvastatin Combined with Ramipril on PAI-1 Antigen Levels (ng/ml) (HC) P=0.828 P= P< Baseline 1 Simvastatin +Placebo 0 Baseline 2 Simvastatin +Ramipril Koh KK, et al. Hypertension. 2004;44:180
28 Additive Beneficial Effects of Ramipril Combined with Simvastatin in the Treatment of Type II Diabetic Patients Kwang Kon Koh, Seung Hwan Han Eak Kyun Shin,. Michael J. Quon AHA 2004, New Orleans, USA Hypertension 2005 (in press)
29 Ramipril Combined with Simvastatin on Blood Pressure (mmhg) 150 *** ** Systolic BP 125 ANOVA p= ** *** Diastolic BP ANOVA p= B1 S B 2 C B 3 R *=p<0.05; **=p<0.01; ***=p<0.001 vs. Baseline. B= Baseline, S=simvastatin+placebo, C=simvastatin+ramipril, R=ramipril+placebo.
30 Effects of Simvastatin, Combined Therapy, % Change in Adiponectin Levels (%) and Ramipril on Insulin Sensitivity Adiponectin P<0.05 P<0.05 P=0.013 by ANOVA % Change in QUICKI (%) QUICKI P<0.05 P<0.05 P=0.015 by ANOVA -10 Simvastatin Combined Therapy Ramipril -5 Simvastatin Combined Therapy Ramipril *QUICKI=Quantitative Insulin-Sensitivity Check Index, a surrogate index of insulin sensitivity, QUICKI = 1/[log(insulin)+log(glucose)] Shin M-S, et al. AHA 2004 Presented
31 Combined Therapy Significantly Improves Flow-mediated Dilator Response 0 Malondialdehyde 100 FMD % Change in MDA Levels (%) P<0.05 P<0.05 Simvastatin Combined Therapy P<0.001 by ANOVA Losartan % Change in Flow-Mediated Dilation (%) P<0.05 P<0.05 Simvastatin Combined Therapy P<0.001 by ANOVA Losartan Koh KK, et al. Circulation. 2004;110:3687
32 ThankQ!
33 Markers of Inflammation and Rapid CAD Progression In 124 Patients with Stable Angina Awaiting PCI Neopterin MMP-9 Waiting Time 4.8 Mo sicam-1 CRP Zouridakis E. Circulation. 2004; 110:1747
34 Fenofibrate Peroxisome Proliferator-Activated Receptors Transcription factors belonging to nuclear receptor superfamily PPARa, PPARb/d, PPARγ Fibrates Synthetic ligands for PPARa PPARa 1. Anti-inflammatory function 2. Reduce oxidative stress 3. Expression of inhibitory protein IkBa Inhibit NF-kB activation
35 Femofibrate increases NO Synthase Expression in BAECs (Western blot) Goya et al, ATVB 2004;24:658
36 Fenofibrate suppresses inflammatory Responses associated with NFkB and IkB in LV of DOCA-salt hypertensive rats
37 Effects of Fenofibrate on Lipoproteins, Vasomotor Function, and Serological Markers of Inflammation, Plaque Stabilization, and Hemostasis Kwang Kon Koh, Seung Hwan Han, Eak Kyun Shin Atherosclerosis 2004;174:379
38 10 Effects of Fenofibrate on Vasomotion in 25 Hypertriglyceridemic Patients FMD (%) NTG (%) 15 P< % Placebo Fenofibrate 0 Placebo Fenofibrate Koh KK et al, Atherosclerosis 2004;174:379
39 Additive Effects of Ramipril Combined with Statin on Inflammation and Fibrinolysis in Patients with CAD Kwang Kon Koh, Seung Hwan Han,. Eak Kyun Shin Atherosclerosis. 2004;177:147
40 % Change in MDA Levels (%) Effects of Simvastatin, Combined Therapy, and Ramipril on MDA Levels and FMD Malondialdehyde P<0.05 P<0.05 Simvastatin Combined Therapy P<0.001 by ANOVA Ramipril Combined Therapy on Flow-Mediated Dilation in Type II Diabetic Patients % Change in Flow-Mediated Dilation (%) P<0.001 FMD P=0.027 P<0.001 Simvastatin Combined Therapy P<0.001 by ANOVA Ramipril
41 Additive Beneficial Effects of Losartan Combined with Simvastatin in Treatment of Hypercholesterolemic, Hypertensive Patients Kwang Kon Koh, Seung Hwan Han Eak Kyun Shin,.. Michael J. Quon* Cardiology, Gachon Medical School, Incheon, Korea Diabetes Unit, NIH, USA* Circulation 2004;110:3687
42 Combined Therapy Significantly Reduces MCP-1 Levels 0 % Change in MCP-1 Levels (%) P<0.05 P<0.05 P=0.030 by ANOVA -30 Simvastatin Combined Therapy Losartan Koh KK, et al. Circulation 2004;110:3687
Welcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationNAM JUNE PAIK: Rhapsody in Video
NAM JUNE PAIK: Rhapsody in Video 혈관연구회추계학회 2007.10.13 Renin-angiotensin-aldosterone System Kwang Kon Koh, MD, FACC, FAHA Cardiology Gachon University Gil Medical Center Incheon, Korea Cytokines oxldl Ang
More informationHypercholesterolemia and hypertension are major
BRIEF REPORT Combination Pravastatin and Valsartan Treatment Has Additive Beneficial Effects to Simultaneously Improve Both Metabolic and Cardiovascular Phenotypes Beyond That of Monotherapy With Either
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationInflammation: Novel Target for Cardiovascular Risk Reduction
Inflammation: Novel Target for Cardiovascular Risk Reduction Andrew Zalewski, M.D. Thomas Jefferson University, Philadelphia GlaxoSmithKline, Philadelphia Why inflammation? Population-based studies: low
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAngiotensin converting enzyme inhibitors remain the first treatment of choice
EDITORIAL Korean J Intern Med 216;31:237-241 Angiotensin converting enzyme inhibitors remain the first treatment of choice Pyung Chun Oh 1,2, Ichiro Sakuma 3, Toshio Hayashi 4, and Kwang Kon Koh 1,2 1
More informationAdipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University
Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationDiabetes and the Heart
Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital
More informationReciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: therapeutic implications
Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: therapeutic implications Michael J. Quon, M.D., Ph.D. Professor of Medicine Professor of Physiology University of Maryland
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationSubclinical inflammation and peripheral artery disease. Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY
Subclinical inflammation and peripheral artery disease Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY ESC Congress 2010 Conflict of interest Research grants:sanofi-aventis,
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationSimvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients KWANG
More informationand Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine
PPAR- Agonist and In-Stent Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine Peroxisome Proliferator- activated Receptors (PPAR) Lipid-activated transcription factors : => regulating
More informationChild born in year /3 will die before parents in US (diabetes)
Child born in year 2000-1/3 will die before parents in US (diabetes) ATP III identified 6 components of the metabolic syndrome that relate to CVD 1. Abdominal obesity 2. Atherogenic dyslipidemia (elevated
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationThe Study of Endothelial Function in CKD and ESRD
The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More information10/17/16. Assessing cardiovascular risk through use of inflammation testing
Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response
More informationEffects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts
Effects of the angiotensin II type-1 receptor antagonist telmisartan on endothelial activation induced by advanced glycation endproducts Serena Del Turco, Teresa Navarra, Giuseppina Basta, Raffaele De
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationDecreased Inflammatory Markers in Diabetic Patients with Angiographically Proved Coronary Artery Disease after 18 Months of Statins Therapy
Decreased Inflammatory Markers in Diabetic Patients with Angiographically Proved Coronary Artery Disease after 18 Months of Statins Therapy DANIEL LIGHEZAN, ROXANA BUZAS, CORINA SERBAN, IOANA SUCEAVA University
More informationInflammatory Markers and Anti- Inflammatory Effects of Insulin
Inflammatory Markers and Anti- Inflammatory Effects of Insulin Paresh Dandona, BSc, MD, DPhil, FRCP, FACP, FACC, FACE Distinguished Professor of Medicine and Pharmacology School of Medicine and Biomedical
More informationRole of Alpha-lipoic acid(ala) and statin in vascular smooth muscle cell proliferation
Role of Alpha-lipoic acid(ala) and statin in vascular smooth muscle cell proliferation In-kyu Lee, M.D., Ph. D. Dept. of Internal Med, Keimyung Univ., School of Med. Taegu, Korea Oxidative Stress and Atherosclerosis
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationBiomarkers in Vascular Inflammation (hscrp, Lp-PLA 2 )
Biomarkers in Vascular Inflammation (hscrp, Lp-PLA 2 ) Inflammation; Current evidence supports a central role in all phases of the atherosclerosis from lesion initiation through to progression and, ultimately,
More informationBerries and Cardiovascular Health
Berries and Cardiovascular Health Britt Burton-Freeman, PhD Institute for Food Safety and Health Illinois Institute of Technology bburton@iit.edu Berry Health Benefits Symposium Westlake Village CA, 2011
More informationATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.
Hyperglycemia and Coronary Events: where is the link? ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Cardiovascular (CV) disease is the primary complication of diabetes ~65% of deaths are due to CV disease Coronary
More informationPEOPLE WITH TYPE 2 diabetes are disproportionately
0163-769X/04/$20.00/0 Endocrine Reviews 25(1):153 175 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/er.2002-0034 Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationAtherosclerosis Regression An Overview of Recent Findings & Issues
Atherosclerosis Regression An Overview of Recent Findings & Issues 13th Angioplasty Summit 2008 Cheol Whan Lee, MD University of Ulsan, Asan Medical Center, Seoul, Korea CardioVascular Research Foundation
More informationThe effect of carotenoids and flavones on oxidative stress in endothelial cells
The effect of carotenoids and flavones on oxidative stress in endothelial cells Esther Paran MD Hypertension Research Center Faculty of Health Sciences Ben-Gurion University Cardiovascular Mortality Risk
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική
ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200
More informationDrugs for Dyslipidemias
Drugs for Dyslipidemias HMG CoA reductase inhibitors (statins): atorvastatin, lovastatin, pravastatin, simvastatin Bile acid-binding resins: cholestyramine, colestipol, colesevelam Fibric acid derivatives
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationC-reactive protein. ; Friend or Foe? Ki Hoon Han MD PhD Asan Medical Center Seoul, Korea
C-reactive protein ; Friend or Foe? Ki Hoon Han MD PhD Asan Medical Center Seoul, Korea I. Inflammation and atherogenesis Atherosclerosis is an inflammatory disease Recruitment of Blood Monocytes by Endothelial
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationMetabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationSeung-Hwan Lee, M.D., Ph.D.
2015.10.16. ICDM, DMJ session Statin discontinuation after achieving a target low-density lipoprotein cholesterol level in type 2 diabetic patients without cardiovascular disease: a randomized controlled
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationUSING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK
USING NON -TRADITIONAL RISK MARKERS IN ASSESSING CV RISK JAMES M FALKO MD PROFESSOR OF MEDICINE UNIVERSITY OF COLORADO Adapted from: Rader D. N Engl J Med. 2000 hs-crp (mg/l) 6 5 4 3 2 1 *p
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationInflammation Biomarkers and Cardiovascular Disease Risk
Chapter 3 Inflammation Biomarkers and Cardiovascular Disease Risk Mary Cushman, Christie M. Ballantyne, Daniel Levy, Nader Rifai, Gerald R. Cooper, and Gary L. Myers RECOMMENDATIONS FOR INFLAMMATION MARKERS
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationClassification of Endothelial Dysfunction. Stefano Taddei Department of Internal Medicine University of Pisa, Italy
Classification of Endothelial Dysfunction Stefano Taddei Department of Internal Medicine University of Pisa, Italy Pathogenesis of atherosclerosis from endothelial dysfunction to clinical disease endothelial
More informationContents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
More informationENDOTHELIAL PROGENITOR CELLS AS A NOVEL BIOMARKER OF VASCULAR HEALTH
ENDOTHELIAL PROGENITOR CELLS AS A NOVEL BIOMARKER OF VASCULAR HEALTH I Jialal, MD, PhD. FRCPath.DABCC Robert E. Stowell Chair in Experimental Pathology Professor of Pathology and Medicine Director, Laboratory
More informationCardiac CT and MR Techniques to Identify the Vulnerable Patient. Are we out of the Gate yet?
Cardiac CT and MR Techniques to Identify the Vulnerable Patient Are we out of the Gate yet? Paolo Raggi, MD Emory University, Atlanta, GA Naghavi, M. et al. Circulation 2003;108:1664-1672 1 Serologic Markers
More informationLIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS Patrick M. Moriarty, M.D., FACP, Director, Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationCurrent Treatment Of Ischemic Heart Disease In the United States: An Overview. By Dr Gary Mo
Current Treatment Of Ischemic Heart Disease In the United States: An Overview By Dr Gary Mo 1 Ischemic Heart Disease in the US 1. Cardiovascular disease remains the most common cause of death and is responsible
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationSequoia Education Systems, Inc.
FMD Training Program: FDMT 545A: Cardiovascular Disease: A Comprehensive Approach to Functional Diagnostic Medicine Training Program Mod 5 * FDMT 545A Cardiovascular Disease: A Comprehensive Approach to
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More information1.6 > < ESRD. < >2.0 ESRD Serum creatinine mg/dl
HMG-CoA Reductase Inhibitors and Renal Function Vito M. Campese, MD Professor of Medicine, Physiology and Biophysics Chief, Division of Nephrology and Hypertension Center Keck School of Medicine, USC Los
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationDepression, omega 3 fatty acid therapy 13
Subject Index Adhesion molecules fish oil effects 12, 13 omega 3 fatty acid desaturase transfection effects on expression in endothelial cells 31 Alzheimer s disease (AD), omega 6 fatty acid/omega 3 fatty
More informationProven and Proposed Cardiovascular Benefits of Soyfoods
Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com Alpro Foundation 20 years symposium
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationStatins and endothelium function
Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationA real life example In human studies, we quantify ~120 plasma related proteins Monocytes MMP9 Macrophages TNFα IL1ß platelet derived growth factor IFNγ MMP1 MMP8 MMP13 Myeloid Related Protein14 CD40
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationHeart Online First, published on March 29, 2005 as /hrt SCIENTIFIC LETTER
Heart Online First, published on March 29, 2005 as 10.1136/hrt.2004.056523 Manuscript ID: HEARTJNL/2004/056523 March 18, 2005 SCIENTIFIC LETTER Effects of HMG-CoA Reductase Inhibition on Endothelial Function
More information